Posted by admin on Jul 31, 2019 in |
Bacterial resistance and oxidative stress are an important etiology of chronic diseases. This is the reason why new alternatives were established to overcome the incidence of some pathologies. Thus, the present study was aimed to evaluate the antibacterial activity of the extracted oil against bacteria that causes nosocomial infections in neonatal intensive care by using disc diffusion method. The antioxidant activity was evaluated using various methods (1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging, reducing power assay, total antioxidant activity) and the content of total phenolic and flavonoids were determined. In the essential oil, the twenty-eight compound was identified by GC/MS analysis. The major components were: 1,8-cineol (26.76%), 1-α-pinene (8.63%), linalool (7.78%). The oil strongly reduced the DPPH radical (IC50 = 4. 4 µg/ml) and reducing of molybdate (0.53 ± 0.0027 mg Eq ascorbic acid/µg EO. The oil showed strong antibacterial activity against nosocomial bacteria tested. This study confirms the essential oil of laurus nobilis. L processes antibacterial and antioxidant properties...
Read More
Posted by admin on Jul 31, 2019 in |
Objective: The antiepileptic potential of the petroleum ether (PETO) and methanolic extracts (METO) of the whole plant (roots, leaves, stem, and bark) of Trema orientalis (family: Ulmaceae) was evaluated using different experimental models of epilepsy in rats and mice. Materials and Methods: The anti-epileptic activity of the PETO and METO was evaluated using Picrotoxin, Isoniazid, and NMDA induced convulsion models. The brain GABA was also estimated in Picrotoxin induced convulsion model. The amount of the Lupeol present in PETO was estimated by HPTLC. Results: Preliminary phytochemical screening of the extracts revealed the presence of phytosterols, triterpenoids, Fixed oils & Fats, Tannins, phenolics, flavonoids, and carbohydrates. The anti-epileptic activity of PETO and METO at doses of 250 mg/kg and 500 mg/kg showed a significant increase (p˂0.001) in the onset of convulsions in the models used. The extracts also showed a significant increase in the brain GABA levels in the doses used. The amount of lupeol present in PETO was estimated to be 8.76 µg/ml. Conclusion: The PETO and METO showed...
Read More
Posted by admin on Jul 31, 2019 in |
The validated analytical method was applied for the estimation of Crisaborole in aqueous and human plasma with Crisaborole-D4 as an internal standard by using UPLC-ESI-MS/MS. The chromatographic separation was achieved with 10mM ammonium acetate buffer solution (pH- 4.5): Methanol, (10:90) (% v/v) using the Xterra C18, 100 × 4.6, 5µ. The total analysis time was 2 min, and the flow rate was set to 0.5 ml/min. The mass transitions of Crisaborole and Crisaborole-D4 obtained were m/z 252.1 ® 222.1 and 256.1 ® 222.1. The standard curve shows a correlation coefficient (r2) greater than 0.999 with a range of 75.00-225.00 ng/ml using the linear regression...
Read More
Posted by admin on Jul 31, 2019 in |
Objective: To develop a simple, accurate and precise method for the simultaneous estimation of Moxifloxacin hydrochloride (MOX) and Vinblastine sulfate (VIN). Methods: The normal spectrum of VIN and MOX were converted to its second derivative spectrum and the amplitude minima of VIN and MOX were measured at 214 nm and 297 nm, respectively. MOX and VIN solution were simultaneously determined in 0.1M HCl at 297 nm and 214 nm. Results: The amplitude of MOX and VIN were found to be more distinct in 0.1M HCl with compared to water, methanol and 0.1M NaOH (order = 2 and Δλ=1). Linearity was obtained over the range 1-8 μg/ml and 3-24 μg/ml with a lower limit of quantitation of 1.7 μg/ml and 0.4 μg/ml for MOX and VIN, respectively. For each level of samples, inter- and intra-day precision (% RSD) was <2.1% and <2.3%for MOX and < 2.3 and <2.7 % for VIN, respectively. The mean recovery of MOX and VIN were in the range 99.98%-103.1%and 101.03%-104.3%, respectively. The developed method was...
Read More
Posted by admin on Jul 31, 2019 in |
The present study was an attempt to investigate the effect of extracts and fractions of Mukia maderaspatana on glycemia, lipid profile, lipoprotein level and antioxidant profile in STZ induced diabetic rats for 21 days. Diabetes was induced using streptozotocin (50 mg/kg i.p) and after the induction of diabetes the animals were given with MMEE (100 mg/kg, 200 mg/kg), MMCF (100 mg/kg) and MMBF (100 mg/kg) orally for 21 days. Blood glucose levels were determined by using GOD-POD method with diagnostic kits. The lipid and lipoprotein level was estimated by using the respective kits. The administration of the extracts orally for 21 days showed that there was an amelioration of the lipid and lipoprotein levels significantly. After 21 days the parameters like HDL, LDL, VLDL, TC, TG, Albumin, Creatinine, total protein and glucose were estimated. The treatment with the extracts and fractions of Mukia maderaspatana improved the lipid level and lipoprotein level to a normal condition which may be attributed to its potent antidiabetic activity. The levels of urea and...
Read More
